KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial.

Rong-Xin Zhang, Xiao-Jun Wu, De-Sen Wan, Jun-Zhong Lin, Pei-Rong Ding, Le-En Liao, Jian Lei, Zhen-Hai Lu, Li-Ren Li, Gong Chen, Ling-Heng Kong, Fu-Long Wang, Jian Zhang, Wen-Hua Fan, Wu Jiang, Wen-Hao Zhou, Cong Li, Yuan Li, Xue-Ying Li, Jian-Hong Peng, Zhi-Zhong Pan

Int J Surg 110(10) 6622-6631

PMID38652147
PMCIDPMC11487029
DOI10.1097/JS9.0000000000001301
发表日期2024-04-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND: The authors aimed to compare combined intraoperative chemotherapy and surgical resection with curative surgical resection alone in colorectal cancer patients. METHODS: The authors performed a multicenter, open-label, randomized, phase III trial. All eligible patients were randomized and assigned to intraoperative chemotherapy and curative surgical resection or curative surgical resection alone (1:1). Survival after long-term follow-up was performed in patients analyzed on an intention-to-treat basis. RESULTS: From January 2011 to January 2016, 696 colorectal cancer patients were enrolled and randomly assigned to intraoperative chemotherapy and radical surgical resection ( n =341) or curative surgical resection alone ( n =344). Intraoperative chemotherapy with surgical resection showed no significant survival benefit over surgical resection alone in colorectal cancer patients [3-year disease-free survival (DFS): 91.1 vs. 90.0%, P =0.328; 3-year OS: 94.4 vs. 95.9%, P =0.756). However, colon cancer patients benefitted from intraoperative chemotherapy, with a relative 4% reduction in liver and peritoneal metastasis (HR=0.336, 95% CI: 0.148-0.759, P =0.015) and a 6.5% improvement in 3-year DFS (HR=0.579, 95% CI: 0.353-0.949, P =0.032). Meanwhile, patients with colon cancer and abnormal pretreatment carcinoembryonic antigen (CEA) levels achieved significant survival benefits from intraoperative chemotherapy (DFS: HR=0.464, 95% CI: 0.233-0.921, P =0.029 and OS: HR=0.476, 95% CI: 0.223-1.017, P =0.049). CONCLUSIONS: Intraoperative chemotherapy showed no significant extra prognostic benefit in total colorectal cancer patients who underwent radical surgical resection; however, in colon cancer patients with abnormal pretreatment serum CEA levels (> 5 ng/ml), intraoperative chemotherapy could improve long-term survival.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 5

(A) Disease-free survival of colon cancer patients; (B) Overall survival of colon cancer patients. (C) Disease-free survival of colon cancer patients with abnormal CEA levels; (D) Overall survival of colon cancer patients with abnormal CEA levels. HR, hazard ratio.

A

liver and peritoneal metastasis rate

Figure 5 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

liver and peritoneal metastasis rate

Figure 5 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

liver and peritoneal metastasis rate

Figure 5 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Flow chart of the intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC) study.
非 KM Figure
Figure 2(A) Disease-free survival of all patients with number at risk; (B) Overall survival of all patients with number at risk. HR, hazard ratio.
非 KM Figure
Figure 3Forest plot of disease-free survival (A) and overall survival (B) in the intraoperative chemotherapy and control groups in stratification analyses. CEA, carcinoembryonic antigen; CA, glucoprotein antigen; HR, hazard ratio; MMR, mismatch repair; pMMR, mismatch repair proficiency; dMMR, mismatch repair deficiency.
非 KM Figure
Figure 4(A) Cumulative hazard of liver and peritoneum metastasis in all patients; (B) Cumulative hazard of liver and peritoneum metastasis in colon cancer patients; (C) Cumulative hazard of liver and peritoneum metastasis in rectal cancer patients. HR, hazard ratio.
非 KM Figure